TY - JOUR
T1 - Validation of the MG-DIS
T2 - a disability assessment for myasthenia gravis
AU - Raggi, Alberto
AU - Leonardi, Matilde
AU - Schiavolin, Silvia
AU - Antozzi, Carlo
AU - Brenna, Greta
AU - Maggi, Lorenzo
AU - Mantegazza, Renato
PY - 2016/3/1
Y1 - 2016/3/1
N2 - This paper is aimed to present the validation of the myasthenia gravis disability assessment (MG-DIS), a MG-specific patient-reported disability outcome measure. Consecutive MG patients were enrolled, followed-up for 12 months and administered the SF-36, the WHO disability assessment schedule (WHODAS 2.0) and the preliminary 31-item MG-DIS addressing impairments and activity limitations. Factor structure and metric properties were assessed. In total, 109 patients were enrolled: 76 were females, mean age 50, mean MG duration 10.4 years, 86 were AChR-positive. The MG-DIS was reduced to 20 items, explaining 70.6 % of the original questionnaire variance, four subscales (generalized impairment-related problems; bulbar function-related problems; mental health and fatigue-related problems; vision-related problems) and an overall disability index. The MG-DIS has good metric properties (Cronbach’s alpha ranging between .808 and .930), is stable, showed to be more sensitive than the WHODAS 2.0 and SF-36 to detect group differences and longitudinal changes and was well correlated with the MG-composite (.642). The MG-DIS includes items representing ocular, generalized, bulbar and respiratory symptoms, and is therefore well-built around MG-specific features. MG-DIS can be used in clinical trials as well as in observational or epidemiological studies to characterize patients’ disability level and address the amount of improvement in disability. Further studies are needed to explore the possibility of a shorter disability scale.
AB - This paper is aimed to present the validation of the myasthenia gravis disability assessment (MG-DIS), a MG-specific patient-reported disability outcome measure. Consecutive MG patients were enrolled, followed-up for 12 months and administered the SF-36, the WHO disability assessment schedule (WHODAS 2.0) and the preliminary 31-item MG-DIS addressing impairments and activity limitations. Factor structure and metric properties were assessed. In total, 109 patients were enrolled: 76 were females, mean age 50, mean MG duration 10.4 years, 86 were AChR-positive. The MG-DIS was reduced to 20 items, explaining 70.6 % of the original questionnaire variance, four subscales (generalized impairment-related problems; bulbar function-related problems; mental health and fatigue-related problems; vision-related problems) and an overall disability index. The MG-DIS has good metric properties (Cronbach’s alpha ranging between .808 and .930), is stable, showed to be more sensitive than the WHODAS 2.0 and SF-36 to detect group differences and longitudinal changes and was well correlated with the MG-composite (.642). The MG-DIS includes items representing ocular, generalized, bulbar and respiratory symptoms, and is therefore well-built around MG-specific features. MG-DIS can be used in clinical trials as well as in observational or epidemiological studies to characterize patients’ disability level and address the amount of improvement in disability. Further studies are needed to explore the possibility of a shorter disability scale.
KW - Disability evaluation
KW - Factor analysis
KW - Myasthenia gravis
KW - Patient-reported outcome
KW - Validation study
UR - http://www.scopus.com/inward/record.url?scp=84959325461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959325461&partnerID=8YFLogxK
U2 - 10.1007/s00415-016-8072-9
DO - 10.1007/s00415-016-8072-9
M3 - Article
AN - SCOPUS:84959325461
SP - 1
EP - 12
JO - Journal of Neurology
JF - Journal of Neurology
SN - 0340-5354
ER -